Tvardi Therapeutics, Inc. (TVRD): R&D Expense
$18.01M
Year ended 2025-12-31
$18.01M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.01M | -23.8% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $23.65M | n/c | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $108.51M | +18.1% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $91.88M | +11.1% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $82.70M | -23.3% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $107.85M | -5.2% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $113.82M | +50.7% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $75.53M | +55.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $48.52M | -1.5% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $49.25M | +132.1% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $21.22M | +40.8% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $15.07M | +73.5% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $8.69M | +88.9% | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | $4.60M | n/a | 2015-03-27, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $18.01M | -23.8% |
| Equillium, Inc. (EQ) | 2025-12-31 | $12.84M | -65.7% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $18.15M | +40.5% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $3.13M | +138.5% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $19.03M | -15.7% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
Compare TVRD, EQ, NVCT, DARE side by side · Screen every company in Pharmaceutical Preparations ↗